Detert, J. and Dziurla, R. and Hoff, P. and Gaber, T. and Klaus, P. and Bastian, H. and Braun, T. and Schellmann, S. and Penzel, T. and Fietze, I. and Loeschmann, P. -A. and Jaehnig, P. and Straub, R. H. and Burmester, G. R. and Buttgereit, F. (2016) Effects of treatment with etanercept versus methotrexate on sleep quality, fatigue and selected immune parameters in patients with active rheumatoid arthritis. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 34 (5). pp. 848-856. ISSN 0392-856X, 1593-098X
Full text not available from this repository. (Request a copy)Abstract
Objective To compare sleep quality, disease activity and patient-reported outcomes such as fatigue and immune parameters in patients with rheumatoid arthritis treated with etanercept (ETA) or methotrexate (MTX). Methods Of 36 patients (28-joint Disease Activity Score, DAS28(CRP)>= 3.2) in this 16-week (w), open, prospective study, 19 (11 women) received MTX 12.5-17 mg/w, and 17 (14 women) received ETA 25 mg x 2/w, alone or in combination with MTX. Clinical (DAS28(CRP), visual analogue scale), laboratory (C-reactive protein [CRP]), sleep (polysomnography), functional (Multidimensional Fatigue Inventory; Health Assessment Questionnaire-Disability Index (HAQ-DI); 36-item Short-Form Health Survey (SF-36), immunological (humoral/cellular) and neuroendocrine (hormonal) parameters were recorded at baseline (BL), w8 and w16. Results BL characteristics did not differ significantly between the ETA and MTX groups except disease duration: mean age (years): 48.6 +/- 8.8 vs. 49.4 +/- 16.6; mean disease duration (months): 19.6 +/- 46.3 vs. 81.2 +/- 79.2; and DAS28CRP: 4.4 +/- 0.9 vs. 4.4 +/- 1.7, respectively. DAS28CRP, SF-36, and HAQ-DI improved significantly in both groups from BL to w16 (p=0.05). The DAS28CRP improvements at w16 (mean changes -1.8 in the ETA group, and -1.4 in MTX group), were not statistically significant from each other. The absolute values of sleep efficiency, total sleep time, and stage 2 sleep duration increased significantly in the ETA group, but no significant changes were reported in the MTX group. Conclusion Both therapies improved disease activity, CRP, SF-36 and HAQ-DI, with faster, more pronounced changes in DAS28CRP in the ETA group, which alone had significantly improved sleep parameters.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | DISEASE-ACTIVITY; GENERAL-POPULATION; DAYTIME SLEEPINESS; MEDICAL OUTCOMES; ALPHA ANTAGONIST; OF-LIFE; PAIN; DISABILITY; LEPTIN; INTERLEUKIN-6; treatment with etanercept versus methotrexate; rheumatoid arthritis; sleep quality; fatique; immune response; endocrinology; interleukin |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin I |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 26 Mar 2019 08:29 |
| Last Modified: | 26 Mar 2019 08:29 |
| URI: | https://pred.uni-regensburg.de/id/eprint/3380 |
Actions (login required)
 |
View Item |
